TPT 0201
Alternative Names: TPT-0201Latest Information Update: 11 Sep 2024
At a glance
- Originator Tetra Pharm Technologies
- Class Antidementias
- Mechanism of Action Fatty acid amide hydrolase inhibitors; Monoacylglycerol lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Mild cognitive impairment
Most Recent Events
- 14 Aug 2024 Preclinical trials in Alzheimer's disease in Denmark (unspecified route) (Tetra Pharm Technologies pipeline, August 2024)
- 14 Aug 2024 Preclinical trials in Mild cognitive impairment in Denmark (unspecified route) (Tetra Pharm Technologies pipeline, August 2024)